---
title: "Labetalol - Hypertensive Disorder"
sidebar: mydoc_sidebar
permalink: db00598-mesh-d006973-1.html
toc: false 
---


Path ID: `DB00598_MESH_D006973_1`
{% include image.html url="images/db00598-mesh-d006973-1.png" file="db00598-mesh-d006973-1.png" alt="db00598-mesh-d006973-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/MESH:D007741">MESH:D007741 </a> | labetalol | Drug |
| <a href="https://identifiers.org/UniProt:P08588">UniProt:P08588 </a> | Beta-1 adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P07550">UniProt:P07550 </a> | Beta-2 adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P35348">UniProt:P35348 </a> | Alpha-1A adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P35368">UniProt:P35368 </a> | Alpha-1B adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P25100">UniProt:P25100 </a> | Alpha-1D adrenergic receptor | Protein |
| <a href="https://identifiers.org/reactome:R-HSA-418555">reactome:R-HSA-418555 </a> | G alpha (s) signalling events | Pathway |
| <a href="https://identifiers.org/reactome:R-HSA-416476">reactome:R-HSA-416476 </a> | G alpha (q) signalling events | Pathway |
| <a href="https://identifiers.org/GO:0042310">GO:0042310 </a> | vasoconstriction | BiologicalProcess |
| <a href="https://identifiers.org/GO:0060047">GO:0060047 </a> | heart contraction | BiologicalProcess |
| <a href="https://identifiers.org/HP:0032263">HP:0032263 </a> | Increased blood pressure | PhenotypicFeature |
| <a href="https://identifiers.org/MESH:D006973">MESH:D006973 </a> | Hypertensive disorder | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Labetalol | NEGATIVELY REGULATES | Beta-1 Adrenergic Receptor |
| Labetalol | NEGATIVELY REGULATES | Beta-2 Adrenergic Receptor |
| Labetalol | NEGATIVELY REGULATES | Alpha-1A Adrenergic Receptor |
| Labetalol | NEGATIVELY REGULATES | Alpha-1B Adrenergic Receptor |
| Labetalol | NEGATIVELY REGULATES | Alpha-1D Adrenergic Receptor |
| Beta-1 Adrenergic Receptor | PARTICIPATES IN | G Alpha (S) Signalling Events |
| Beta-2 Adrenergic Receptor | PARTICIPATES IN | G Alpha (S) Signalling Events |
| Alpha-1A Adrenergic Receptor | PARTICIPATES IN | G Alpha (Q) Signalling Events |
| Alpha-1B Adrenergic Receptor | PARTICIPATES IN | G Alpha (Q) Signalling Events |
| Alpha-1D Adrenergic Receptor | PARTICIPATES IN | G Alpha (Q) Signalling Events |
| G Alpha (S) Signalling Events | POSITIVELY CORRELATED WITH | Heart Contraction |
| G Alpha (Q) Signalling Events | POSITIVELY CORRELATED WITH | Vasoconstriction |
| Heart Contraction | POSITIVELY CORRELATED WITH | Increased Blood Pressure |
| Vasoconstriction | POSITIVELY CORRELATED WITH | Increased Blood Pressure |
| Increased Blood Pressure | MANIFESTATION OF | Hypertensive Disorder |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB00598](https://go.drugbank.com/drugs/DB00598)
